ASH News Daily 2013 - Day 1 - (Page B-1)

Read this issue online at www.hematology.org/ashnewsdaily2013_saturday Follow us on Twitter using #ASH13 SCheDuLe 7:00 a.m. - 6:00 p.m. Registration Ernest N. Morial Convention Center Great Hall 7:30 - 9:00 a.m. Education/Scientific Program 9:00 a.m. - 7:30 p.m. Poster Session I - Viewing Ernest N. Morial Convention Center Halls E and G 9:30 - 11:00 a.m. Education/Scientific Program 11:00 a.m. - 5:00 p.m. Exhibits Open Ernest N. Morial Convention Center Halls B-D 11:15 a.m. - 12:15 p.m. Career-Development Lunch Sessions Open only to trainees wearing a blue badge 11:30 a.m. - 12:30 p.m. Product Theaters in Exhibit Hall Halls B-D 2:00 - 3:30 p.m. Education/Scientific Program 4:00 - 5:30 p.m. Education/Scientific Program 5:30 - 7:30 p.m. Poster Session I - Presentations Ernest N. Morial Convention Center Halls E and G IN THIS SECTION Minority Medical Student Awards B-5 Catching Up with TRTH Participants B-8 Trainee Events and Services B-16 International Members Committee B-23 Dining in the Big Easy B-40 The Blood Journal in 2013 and Forward Highlighting Clinical and Scientific Excellence By BoB LöwenBerg, MD, PhD, eDitor-in-Chief, anD nanCy BerLiner, MD, DePuty eDitor B lood is the leading biomedical journal in hematology. From its early days, it has sought to represent the full spectrum of subdisciplines and subspecialties in hematology. The Journal's focus is, and has always been, on clinical and biological, basic and applied developments of interest in the field. It is our foremost and absolute priority to deliver important, novel scientific and educational information to our readers as promptly as possible. With this in mind, we have been working on maximizing the interest of the content for our colleagues in clinical practice. Several features serve this goal in the Jour- nal. The recently launched Spotlight Reviews use a concise format to highlight emerging areas of relevance to hematology, including subjects of diagnostic and therapeutic importance. The Spotlight Reviews on the promising new myeloma drug pomalidomide and the diagnosis of acute pulmonary embolism are examples. The Review Series was launched this year and offers collections of reviews that place new developments on a related theme in a comprehensive scientific and clinical perspective. We hope that these reviews are attractive to clinicians and scientists alike. Two recent Series cover cancer-associated thrombotic disease and the emerging role of nextgeneration sequencing in hematology. We have actively continued to publish Perspectives and Reviews with a clinical orientation (e.g., "A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis") as well as our Blood Consults, the Evidence-Based Focused Reviews (e.g., "Treatment of acquired von Willebrand syndrome in childhood"), and our CME articles. These features should serve our readers working in clinical practice. The same applies to the Clinical Recommendation and Guideline papers that appear on a regular basis in the Journal. The important European LeukemiaNet recommendations for the management of chronic myeloid leukemia have been published, and an analogous recommendation paper on the management of MDS recently appeared in the Journal. The results of major clinical trials in various areas in hematology, obviously too many to list here, are frequently also published in our pages. Blood's "How I Treat" articles have gained a special position over the years and represent a fascinating diversity of our clinical field and the clinical challenges that we »» JOURNAL Page B-4 Reception Honors 2014 ASH-AMFDP Award Winners and 2013 MMSAP Participants T his evening, ASH will host the annual Promoting Minorities in Hematology Presentations and Reception. While providing a forum to network with colleagues, medical students, and ASH leadership, the reception will showcase training and research opportunities geared toward increasing the diversity of scholars in the field of hematology. Attendees will also learn about the details of the Society's Minority Medical Student Award Program (MMSAP) and the ASH-Harold Amos Faculty Development Program (AMFDP). The event will be held from 6:30 to 9:30 p.m. in the Napoleon Ballroom at the Hilton New Orleans Riverside. At this evening's reception, 15 MMSAP participants will present their summer research projects. During the presentations, the 2014 ASH-AMFDP recipients, Esther Obeng, MD, PhD, and Abner Louissaint, MD, PhD, will also be announced. Dr. Obeng is an instructor in pediatrics at Harvard Medical School in Boston, working in the laboratory of Benjamin Ebert, MD. Her clinical Abner Louissaint, MD, PhD Esther Obeng, MD, PhD interests are in stem cell transplantation and bone marrow failure. Dr. Brigham and Women's Hospital in Obeng is also an attending physi- the Department of Newborn Medician at Boston Children's Hospital cine. Upon receipt of her BS, she in the Division of Hematology/ continued at the University of MiOncology, an attending physician ami to obtain her MD and PhD. Her at Dana-Farber Institute in the graduate work was supported by Department of Pediatric Oncology, and a consulting physician at »» ASH-AMFDP Page B-3 http://www.hematology.org/ashnewsdaily2013_saturday

Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 1

Table of Contents

ASH News Daily 2013 - Day 1

https://www.nxtbookmedia.com